Evidence map›Paper›PMID 34122779›Full record

ArticleJournal of extracellular vesicles2021

Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EV-CATCHER): A customizable purification assay designed for small-RNA biomarker identification and evaluation of circulating small-EVs.

Megan I Mitchell, Iddo Z Ben-Dov, Christina Liu, Kenny Ye, Kar Chow, Yael Kramer, Anju Gangadharan, Steven Park, Sean Fitzgerald, Andrew Ramnauth and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06798558 (Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06798558 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

TypeinterventionalSponsorHackensack Meridian HealthRan2025 to 2029Enrolled54ConditionsProstate AdenocarcinomaArmsLu-17-PSMA-617
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Megan I MitchellCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.ORCID 0000-0002-1202-155X
Iddo Z Ben-DovLaboratory of Medical Transcriptomics Hadassah-Hebrew University Medical Center Jerusalem Israel.
Christina LiuCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Kenny YeDepartment of Epidemiology and Population Health Albert Einstein College of Medicine Bronx New York USA.
Kar ChowBiorepository Hackensack University Medical Center Hackensack New Jersey USA.
Yael KramerBiorepository Hackensack University Medical Center Hackensack New Jersey USA.
Anju GangadharanBiorepository Hackensack University Medical Center Hackensack New Jersey USA.
Steven ParkCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Sean FitzgeraldCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Andrew RamnauthDepartment of Pathology and Laboratory Medicine Weill Cornell Medicine New York USA.
David S PerlinCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Michele DonatoBiorepository Hackensack University Medical Center Hackensack New Jersey USA.
Emily BhoyCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Ehsan Manouchehri DoulabiDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University Uppsala Sweden.
Michael PoulosCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Masood Kamali-MoghaddamDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University Uppsala Sweden.
Olivier LoudigCenter for Discovery and Innovation Hackensack Meridian Health Nutley New Jersey USA.
Hackensack Meridian Health · USHackensack University Medical Center · USUppsala University · SEAlbert Einstein College of Medicine · USCornell University · USHadassah Medical Center · IL

Funding

Exhaled small RNA biomarkers to detect and monitor airway diseaseR33HL156279 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI LOUDIG, OLIVIER, SPIVACK, SIMON D · 2021 to 2022
$1.0M
NHLBI NIH HHS R33 HL156279
6 · The paper itself

Abstract

Circulating nucleic acids, encapsulated within small extracellular vesicles (EVs), provide a remote cellular snapshot of biomarkers derived from diseased tissues, however selective isolation is critical. Current laboratory-based purification techniques rely on the physical properties of small-EVs rather than their inherited cellular fingerprints. We established a highly-selective purification assay, termed EV-CATCHER, initially designed for high-throughput analysis of low-abundance small-RNA cargos by next-generation sequencing. We demonstrated its selectivity by specifically isolating and sequencing small-RNAs from mouse small-EVs spiked into human plasma. Western blotting, nanoparticle tracking, and transmission electron microscopy were used to validate and quantify the capture and release of intact small-EVs. As proof-of-principle for sensitive detection of circulating miRNAs, we compared small-RNA sequencing data from a subset of small-EVs serum-purified with EV-CATCHER to data from whole serum, using samples from a small cohort of recently hospitalized Covid-19 patients. We identified and validated, only in small-EVs, hsa-miR-146a and hsa-miR-126-3p to be significantly downregulated with disease severity. Separately, using convalescent sera from recovered Covid-19 patients with high anti-spike IgG titers, we confirmed the neutralizing properties, against SARS-CoV-2 in vitro, of a subset of small-EVs serum-purified by EV-CATCHER, as initially observed with ultracentrifuged small-EVs. Altogether our data highlight the sensitivity and versatility of EV-CATCHER.

Indexed as

AnimalsBodily SecretionsChlorocebus aethiopsCirculating MicroRNACOVID-19Extracellular VesiclesHigh-Throughput Nucleotide SequencingHumansImmunologic TechniquesMCF-7 CellsMiceRAW 264.7 CellsSeverity of Illness IndexVero CellsCirculating MicroRNAexosome purificationextracellular vesiclesmicro‐RNA profilingsequencingTEM

Identifiers

PMID34122779
PMCPMC8173589
OpenAlexW3172985871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.